Search bioRxiv⌕ Search

Biology subjects

Kowalski, J.

Publications and source records attributed to Kowalski, J..

11 recordsLinked to original sources

Active Learning for Budget-Constrained TCR--pMHC Wet-Lab Validation

Wet-lab validation of TCR-pMHC binding hypotheses is the rate-limiting step in T-cell therapy discovery: a single binding assay round can cost thousands of dollars and weeks of turnaround time, yet computational models generate thousands of candidate pairs per run. We frame this as a pool-based active learning problem: given a fixed annotation budget B, which unlabeled pairs should be sent to the assay to maximally improve a predictive model that will guide the next screening round? We introduce UDAL (Uncertainty-Diversity Active Learning), a batch acquisition strategy that combines BALD-based uncertainty estimation via MC Dropout with greedy core-set diversity selection in the encoder feature space. Evaluated on a curated VDJdb-IEDB benchmark under epitope-held-out and distance-aware protocols, UDAL achieves AUPRC 0.487 with only 5,000 queried labels--matching the performance of a model trained on 3 x more randomly sampled labels. At a budget of 2,000 labels, UDAL improves AUPRC by 16.7% over random acquisition, translating directly to fewer wasted assay slots. These results demonstrate that principled active query strategies can substantially reduce the wet-lab cost of building reliable TCR specificity models.

bioinformatics↗

FairTCR: Equity-Aware TCR--pMHC Binding Prediction\\Across HLA Alleles and Cohort Strata

Public TCR-pMHC binding databases are heavily skewed toward a handful of well-studied HLA alleles-- most prominently HLA-A*02:01, which covers [~]45% of curated records--and toward patients from European-ancestry cohorts. Standard empirical risk minimization (ERM) trained on such data achieves strong pooled accuracy but routinely underperforms on rare alleles and underrepresented cohorts, creating systematic disparities that are invisible in single-metric benchmarks. We introduce FairTCR, a group distributionally robust optimization (GDRO) framework that minimizes worstgroup loss across HLA supertypes and cohort strata via online exponentiated gradient updates. FairTCR reduces the average- worst-group AUPRC disparity from 0.190 (ERM) to 0.098 on a curated VDJdb-IEDB benchmark, achieving a 48.4% disparity reduction while maintaining competitive average AUPRC (0.432 vs. 0.431 for ERM). Per-HLA analysis shows that rare allele groups (B*08:01, B*44:02) gain up to 0.062 AUPRC points, directly improving the equity of computational pre-screening for underrepresented patient populations.

bioinformatics↗

Frequently Together, Among Model Systems Molecular Alterations: Cancer Maintenance Markers with Translational Study Design

In contrast to cancer driver gene alterations, genes with alterations occurring frequently together are unlikely to play a direct role in tumor development, and more likely to contribute to normal cellular functions necessary for the ongoing maintenance and survival of the tumor, with the most robust of these genes preserved across model systems. We introduce two molecular signature-centric methods, RECO (recurring and co-occurring) and Crosstalk, to identify gene sets characterized by molecular alterations that occur frequently together across sample model systems. Our overall approach builds a cancer information exchange among samples systems based on an analysis of gene and sample-level signature pairs using RECO and Crosstalk methods. The results may be used to design translational studies from gene signature discovery in patients to its application in cell lines and patient-derived xenograft models, alongside the discovery of potential cancer maintenance markers. We demonstrate the capabilities of our approach by exploring the discovery of frequently together molecular alterations between patient tumors and cell lines, and between histologically similar tumors with different sites of origin, and their associations with outcomes in several cancers. As understudied, expanded markers, genes with frequently occurring molecular alterations between systems offer potentially new insights into similar cancer etiology and treatment targets outside the norm, in addition to informing on translational study design. Availability and implementation: The method is implemented at: https://github.com/kmlabdms/CIERCE

bioinformatics↗

TTSBBC: Triplex Target Site Biomarkers and Barcodes in Cancer

The technology of Triplex-forming oligonucleotides (TFOs) provides an approach to manipulate genes at the DNA level. TFOs bind to specific sites on genomic DNA, creating a unique intermolecular triple-helix DNA structure through Hoogsteen hydrogen bonding. This targeting by TFOs is site-specific and the locations TFOs bind are referred to as TFO target sites (TTS). Triplexes have been observed to selectively influence gene expression, homologous recombination, mutations, protein binding, and DNA damage. These sites typically feature a poly-purine sequence in duplex DNA, and the characteristics of these TTS sequences greatly influence the formation of the triplex. We introduce TTSBBC, a novel analysis and visualization platform designed to explore features of TTS sequences to enable users to design and validate TTSs. The web server can be freely accessed at https://kowalski-labapps.dellmed.utexas.edu/TTSBC/.

bioinformatics↗

NBBC: Quantifying the Prevalence of Non-B DNA Motifs as a Marker of Non-B Burden in Cancer

Alternative DNA structures, such as Z-DNA, G-quadruplexes, and mirror repeats, have shown potential involvement in cancer etiology. NBBC (Non-B DNA Burden in Cancer) is a web-based tool designed for quantifying and analyzing non-B DNA motifs within a cancer context. Herein, we provide a step-by-step protocol for employing NBBC, starting with data input and proceeding through the quantification and normalization of non-B DNA motifs that result in calculation of non-B burden. With detailed instructions for performing various motif-centric analyses based on cancer gene signatures, including DNA damage repair and response pathways for exploring genomic stability, and sample-level gene mutation signatures, a user is able to explore non-B associative correlations within current cancer biology. We provide additional detail on input queries into NBBC, interpret the quantitative results, and apply normalization techniques to ensure accurate comparisons across different genomic regions and non-B DNA structures. NBBC offers a powerful and user-friendly interface for the cancer research community. This chapter serves as an essential, enhanced instructional guide for researchers to leverage NBBC in their cancer biomarker investigations for an understanding of the potential role of non-B DNA in contributing to them.

cancer biology↗

Non-B DNA-Informed Mutation Burden as a Marker of Treatment Response and Outcome in Cancer

BackgroundGenomic instability plays a key role in tumorigenesis and cancer research, with Tumor Mutation Burden (TMB) being a crucial biomarker quantifying total mutation to indicate therapeutic effectiveness, particularly in immunotherapy. However, TMB is not always a reliable predictor of treatment response and displays heterogeneity. Non-B DNA, alternative DNA forms have the potential to increase susceptibility to mutations that lead to the development of cancer. The tendency of these structures to induce mutations highlights their critical role in cancer onset and advancement, indicating their potential merit when combined with mutation information for enhanced markers in cancer with potential novel insights. Methods and findingsWe introduce two novel markers, "nbTMB" (non-B-informed tumor mutation burden) and "mlTNB" (mutation-localized-informed tumor non-B burden). We show in three separate case studies applying these markers the following findings: 1) nbTMB informs on survival heterogeneity among TMB-High patients undergoing immunotherapy whereas TMB is unable to further differentiate; 2) nbTMB informs on altered cisplatin sensitivity among ovarian cancer patient-derived cell lines whereas TMB is unable to differentiate; and 3) mlTNB informs on survival heterogeneity among early stage pancreatic cancer progressors in whom other markers of genomic instability fail to differentiate. ConclusionsThese novel markers offer a nuanced approach in which to enhance our current understanding of treatment responses and outcomes in cancer, underscoring the need for a more comprehensive exploration of the interplay between non-B and B-DNA features.

cancer biology↗

MoCoLo: a testing framework for motif co-localization

Sequence-level data offers insights into biological processes through the interaction of two or more genomic features from the same or different molecular data types. Within motifs, this interaction is often explored via the co-occurrence of feature genomic tracks using fixed-segments or analytical tests that respectively require window size determination and risk of false positives from over-simplified models. Moreover, methods for robustly examining the co-localization of genomic features, and thereby understanding their spatial interaction, have been elusive. We present a new analytical method for examining feature interaction by introducing the notion of reciprocal co-occurrence, define statistics to estimate it, and hypotheses to test for it. Our approach leverages conditional motif co-occurrence events between features to infer their co-localization. Using reverse conditional probabilities and introducing a novel simulation approach that retains motif properties (e.g., length, guanine-content), our method further accounts for potential confounders in testing. As a proof-of-concept, MoCoLo confirmed the co-occurrence of histone markers in a breast cancer cell line. As a novel analysis, MoCoLo identified significant co-localization of oxidative DNA damage within non-B DNA forming regions that significantly differed between non-B DNA structures. Altogether, these findings demonstrate the potential utility of MoCoLo for testing spatial interactions between genomic features via their co-localization.

bioinformatics↗

Transcription Factor EB (TFEB) activity increases resistance of TNBC stem cells to metabolic stress

Breast Cancer Stem Cells (CSCs) are difficult to therapeutically target, but continued efforts are critical given their contribution to tumor heterogeneity and treatment resistance in Triple-Negative Breast Cancer (TNBC). CSC properties are influenced by metabolic stress, but specific mechanisms are lacking for effective drug intervention. Our previous work on TFEB suggested a key function in CSC metabolism. Indeed, TFEB knockdown (KD) inhibited mammosphere formation in vitro and tumor initiation/growth in vivo. These phenotypic effects were accompanied by a decline in CD44high/CD24low cells. Glycolysis inhibitor 2-deoxy-D-glucose (2-DG) induced TFEB nuclear translocation, indicative of TFEB transcriptional activity. TFEB KD blunted, whereas TFEB (S142A) augmented 2-DG-driven UPR mediators, notably BiP/HSPA5 and CHOP. Like TFEB KD, silencing BiP/HSPA5 inhibited CSC self-renewal, suggesting that TFEB augments UPR-related survival. Further studies showed that TFEB KD attenuated 2-DG-directed autophagy, suggesting a mechanism whereby TFEB protects CSCs against 2-DG-induced stress. Our data indicate that TFEB modulates CSC metabolic stress response via autophagy and UPR. These findings reveal the novel role of TFEB in regulating CSCs during metabolic stress in TNBC. Financial SupportThis work was supported by CPRIT Grant RR160093 (to S.G. Eckhardt), CPRIT Grant RP210088 (to K.N. Dalby), UT College of Pharmacy Non-discretionary Funds (to C. Van Den Berg), and UT Graduate Continuing Fellowship (to M. Soleimani).

cancer biology↗

Comprehensive cancer-oriented biobanking resource of human samples for studies of post-zygotic genetic variation involved in cancer predisposition

The progress in translational cancer research relies on access to well-characterized samples from a representative number of patients and controls. The rationale behind our biobanking are explorations of post-zygotic pathogenic gene variants, especially in non-tumoral tissue, which might predispose to cancers. The targeted diagnoses are carcinomas of the breast (via mastectomy or breast conserving surgery), colon and rectum, prostate, and urinary bladder (via cystectomy or transurethral resection), exocrine pancreatic carcinoma as well as metastases of colorectal cancer to the liver. The choice was based on the high incidence of these cancers and/or frequent fatal outcome. We also collect age-matched normal controls. Our still ongoing collection originates from five clinical centers and after nearly 2-year cooperation reached 1711 patients and controls, yielding a total of 23226 independent samples, with an average of 74 donors and 1010 samples collected per month. The predominant diagnosis is breast carcinoma, with 933 donors, followed by colorectal carcinoma (383 donors), prostate carcinoma (221 donors), bladder carcinoma (81 donors), exocrine pancreatic carcinoma (15 donors) and metachronous colorectal cancer metastases to liver (14 donors). Forty percent of the total sample count originates from macroscopically healthy cancer-neighboring tissue, while contribution from tumors is 12%, which adds to the uniqueness of our collection for cancer predisposition studies. Moreover, we developed two program packages, enabling registration of patients, clinical data and samples at the participating hospitals as well as the central system of sample/data management at coordinating center. The approach used by us may serve as a model for dispersed biobanking from multiple satellite hospitals. Our biobanking resource ought to stimulate research into genetic mechanisms underlying the development of common cancers. It will allow all available "-omics" approaches on DNA-, RNA-, protein- and tissue levels to be applied. The collected samples can be made available to other research groups.

cancer biology↗

An experimental-mathematical approach to predict tumor cell growth as a function of glucose availability in breast cancer cell lines

We present the development and validation of a mathematical model that predicts how glucose dynamics influence metabolism and therefore tumor cell growth. Glucose, the starting material for glycolysis, has a fundamental influence on tumor cell growth. We employed time-resolved microscopy to track the temporal change of the number of live and dead tumor cells under different initial glucose concentrations and seeding densities. We then constructed a family of mathematical models (where cell death was accounted for differently in each member of the family) to describe overall tumor cell growth in response to the initial glucose and confluence conditions. The Akaikie Information Criteria was then employed to identify the most parsimonious model. The selected model was then trained on 75% of the data to calibrate the system and identify trends in model parameters as a function of initial glucose concentration and confluence. The calibrated parameters were applied to the remaining 25% of the data to predict the temporal dynamics given the known initial glucose concentration and confluence, and tested against the corresponding experimental measurements. With the selected model, we achieved an accuracy (defined as the fraction of measured data that fell within the 95% confidence intervals of the predicted growth curves) of 77.2 {+/-} 6.3% and 87.2 {+/-} 5.1% for live BT-474 and MDA-MB-231 cells, respectively.

cancer biology↗

NOJAH: Not Just Another Heatmap for Genome-Wide Cluster Analysis

Since their inception, several tools have been developed for cluster analysis and heatmap construction. The application of such tools to the number and types of genome-wide data available from next generation sequencing (NGS) technologies requires the adaptation of statistical concepts, such as in defining a most variable gene set, and more intricate cluster analyses method to address multiple omic data types. Additionally, the growing number of publicly available datasets has created the desire to estimate the statistical significance of a gene signature derived from one dataset to similarly group samples based on another dataset. The currently available number of tools and their combined use for generating heatmaps, along with the several adaptations of statistical concepts for addressing the higher dimensionality of genome-wide NGS-derived data, has created a further challenge in the ability to replicate heatmap results. We introduce NOJAH (NOt Just Another Heatmap), an interactive tool that defines and implements a workflow for genome-wide cluster analysis and heatmap construction by creating and combining several tools into a single user interface. NOJAH includes several newly developed scripts for techniques that though frequently applied are not sufficiently documented to allow for replicability of results. These techniques include: defining a most variable gene set (a.k.a., core genes), estimating the statistical significance of a gene signature to separate samples into clusters, and performing a result merging integrated cluster analysis. With only a user uploaded dataset, NOJAH provides as output, among other things, the minimum documentation required for replicating heatmap results. Additionally, NOJAH contains five different existing R packages that are connected in the interface by their functionality as part of a defined workflow for genome-wide cluster analysis. The NOJAH application tool is available at http://bbisr.shinyapps.winship.emory.edu/NOJAH/ with corresponding source code available at https://github.com/bbisr-shinyapps/NOJAH/.

bioinformatics↗